Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
AD Seidman, CA Hudis, J Albanell, J Albanel… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE To evaluate the efficacy and toxicity of paclitaxel administered as a 1-hour infusion
on weekly basis, without interruption, to patients with metastatic breast cancer who had …
on weekly basis, without interruption, to patients with metastatic breast cancer who had …
Mechanism of action of anti-HER2 monoclonal antibodies
J Baselga, J Albanell - Annals of oncology, 2001 - Elsevier
The search for new methods of treating cancer, combined with advances in our understanding
of carcinogenesis, molecular biology and technology, has resulted in the development of …
of carcinogenesis, molecular biology and technology, has resulted in the development of …
Mechanism of action of trastuzumab and scientific update
The humanized anti-p185 HER2 monoclonal antibody trastuzumab has been shown to
effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The …
effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The …
Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing …
J Baselga, L Norton, J Albanell, YM Kim, J Mendelsohn - Cancer research, 1998 - AACR
Recombinant humanized anti-HER2 antibody, rhuMAb HER2, inhibits the growth of breast
cancer cells overexpressing HER2 and has clinical activity. We explored in preclinical models …
cancer cells overexpressing HER2 and has clinical activity. We explored in preclinical models …
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
HER2 is a ligand-less tyrosine kinase receptor of the ErbB family that is frequently overexpressed
in breast cancer. It undergoes proteolytic cleavage that results in the release of the …
in breast cancer. It undergoes proteolytic cleavage that results in the release of the …
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …
…, H Swaisland, F Rojo, J Albanell - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic …
growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic …
A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition
Epithelial–mesenchymal transition (EMT) is essential for organogenesis and is triggered
during carcinoma progression to an invasive state 1 . Transforming growth factor-β (TGF-β) …
during carcinoma progression to an invasive state 1 . Transforming growth factor-β (TGF-β) …
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of …
J Albanell, F Rojo, S Averbuch… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa;
AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom) is under development …
AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom) is under development …
[PDF][PDF] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga, J Albanell, A Ruiz, A Lluch, P Gascón… - J Clin Oncol, 2005 - academia.edu
… J Mammary Gland Biol Neoplasia 2:131-141, 1997 10. Klijn JG, Berns PM, Schmitz PI, et
al: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast …
al: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast …
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
…, A Rovira, J Settleman, F Bosch, J Albanell - Nature medicine, 2012 - nature.com
Antibodies against epidermal growth factor receptor (EGFR)—cetuximab and panitumumab—are
widely used to treat colorectal cancer. Unfortunately, patients eventually develop …
widely used to treat colorectal cancer. Unfortunately, patients eventually develop …